Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026

SIGA vs ANTX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ANTX Captures Overall Composite Edge (37.2 SELL vs 47.5 HOLD), While SIGA Leads 4–1 on Growth & Valuation Pillars

ANTX Overall Winner 6-Pillar Tally: SIGA 4 – 1 ANTX (1 Tie) Matrix Metrics: SIGA 5 – 3 ANTX

As of Nov 19, 2026, AN2 Therapeutics, Inc. (ANTX) captures the overall head-to-head institutional edge over SIGA Technologies Inc. (SIGA) on higher Unified Composite conviction (37.2/100 SELL vs. 47.5/100 HOLD) after splitting the core matrix 3–5 (led by Growth & Scale), while SIGA wins 4–1 across the 6-pillar growth and valuation breakdown. SIGA trades at $2.65 (2.5x Forward P/E, -14.2% operating margin) versus ANTX at $5.22 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While SIGA currently prints a higher short-term Unified Composite Score (47.5/100 HOLD vs. ANTX 37.2/100 SELL), ANTX captures the overall institutional head-to-head verdict (3–5 matrix metrics and 1–4 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -14.2% operating margin) and revenue trajectory (+0.0% vs. -49.7% YoY).
  • Technical & Structure Timing Caution: SIGA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.7); meanwhile ANTX trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 65.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About SIGA vs ANTX
SIGA NASDAQ
SIGA Technologies Inc.
Pharmaceutical Preparations
$2.65
-5.36% 1D
Market Cap $187.9M
TTM Revenue $52M
Forward P/E 2.5x
Beta / 30D Vol 0.75β · 65% Vol
Unified Composite Score
47.5 / 100 HOLD
Tech 40.0 Fund 56.0 Flow 69.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -0.6%), weak momentum, RSI 37
RSI-14: 36.7 · SMA20: $3.02 · SMA50: $3.14
ANTX NASDAQ Head-to-Head Winner
AN2 Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$5.22
+5.45% 1D
Market Cap $190.1M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.75β · 98% Vol
Unified Composite Score
37.2 / 100 SELL
Tech 15.0 Fund 39.0 Flow 69.0 Mom 40.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 65
RSI-14: 65.0 · SMA20: $4.31 · SMA50: $4.52

6-Pillar Scorecard Institutional Category Breakdown (SIGA 4 – 1 ANTX)

Columns: Metric · SIGA · ANTX
1. Valuation Multiples SIGA
Forward P/E 2.5x N/M
Trailing P/E N/M N/M
PEG Ratio 3.37x N/M
EV / Revenue 1.4x N/M
2. Growth & Scale ANTX
Revenue Growth (YoY) -49.7% +0.0%
Earnings Growth (YoY) -65.3% +0.0%
TTM Revenue (USD) $52M N/A
Market Cap $187.9M $190.1M
3. Profitability & Quality SIGA
Gross Margin 23.4% N/A
Operating Margin -14.2% 0.0%
Net Profit Margin 1.3% 0.0%
Return on Equity (ROE) 0.4% -51.3%
4. Balance Sheet & Cash Flow SIGA
Cash Generation (TTM) -$12M -$30M
Cash Flow Margin -22.1% N/A
Net Cash / Leverage $116M Net Cash $1.99 Book/Sh · -51.3% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase CONSOLIDATION CONSOLIDATION
Current IV / %ile 81.4% (8th %ile) 134.2% (22nd %ile)
Put/Call OI Skew 0.04x (Call-Skewed) N/A
OBV Trend / Tech Phase DISTRIBUTION · Markdown NEUTRAL · Neutral
6. R&D & Supply-Chain Moat SIGA
OpEx & R&D Intensity 37.6% of Rev ($20M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Drug Manufacturers - Specialty & Generic Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: SIGA (5) vs ANTX (3)
Institutional Metric SIGA ANTX Criterion Row Edge
Market Capitalization
Scale
$187.9M $190.1M Larger Scale Tie
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
2.5x N/M Lower Multiple SIGA
Revenue Growth (YoY)
Growth
-49.7% +0.0% Higher Growth ANTX
Operating Margin (TTM)
Profitability
-14.2% 0.0% Higher Margin ANTX
Net Profit Margin
Profitability
1.3% 0.0% Higher Margin SIGA
Return on Equity (ROE)
Capital Efficiency
0.4% -51.3% Higher ROE SIGA
52-Week Range Position
Momentum
3% ($3–$7) 68% ($1–$7) Stronger Trend ANTX
Beta / 30D Volatility
Risk Regime
0.75β · 65% Vol 0.75β · 98% Vol Lower Realized Risk SIGA
Unified Institutional Score
Composite Signal
47.5 / 100 (HOLD) 37.2 / 100 (SELL) Higher Composite SIGA
Trailing 12M Revenue (USD)
Operating Scale
$52M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
23.4% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
3.37x PEG · 1.4x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$12M ($116M Net Cash) -$30M ($1.99 Book/Sh · -51.3% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ANTX +60.06 pp
SIGA: -15.06% · ANTX: +45.0%
3M Horizon ANTX +2.68 pp
SIGA: -12.83% · ANTX: -10.15%
6M Horizon ANTX +50.49 pp
SIGA: -43.74% · ANTX: +6.75%
1Y Horizon ANTX +421.68 pp
SIGA: -55.61% · ANTX: +366.07%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SIGA vs ANTX. Trailing 12-month operating profitability (SIGA -14.2% vs ANTX 0.0%) and valuation multiples (SIGA 2.5x vs ANTX N/M Forward P/E) are benchmarked directly in Pillar 4 below.

SIGA ADR TTM Benchmark FX-Normalized USD
TTM Revenue$52M
Gross Margin23.4%
Op. Margin-14.2%
ROE / Fwd P/E0.4% · 2.5x
ANTX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-51.3% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
SIGA CONSOLIDATION
33d in phase · OBV DISTRIBUTION
Current IV 81.4%
IV Percentile 8th %ile
Put/Call OI Skew 0.04x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact SIGA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ANTX CONSOLIDATION
177d in phase · OBV NEUTRAL
Current IV 134.2%
IV Percentile 22nd %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact ANTX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
SIGA Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $187.9M market capitalization and -14.2% operating margin.
OpEx & R&D Reinvestment 37.6% of Rev ($20M)
90D Engineering Disclosures 0 Published
ANTX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $190.1M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ SIGA vs ANTX Key Questions & Quantitative Answers

As of Nov 19, 2026, AN2 Therapeutics, Inc. (ANTX) captures the overall head-to-head institutional edge over SIGA Technologies Inc. (SIGA) on higher Unified Composite conviction (37.2/100 SELL vs. 47.5/100 HOLD) after splitting the core matrix 3–5 (led by Growth & Scale), while SIGA wins 4–1 across the 6-pillar growth and valuation breakdown. SIGA trades at $2.65 (2.5x Forward P/E, -14.2% operating margin) versus ANTX at $5.22 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While SIGA currently prints a higher short-term Unified Composite Score (47.5/100 HOLD vs. ANTX 37.2/100 SELL), ANTX captures the overall institutional head-to-head verdict (3–5 matrix metrics and 1–4 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -14.2% operating margin) and revenue trajectory (+0.0% vs. -49.7% YoY). Technical & Structure Timing Caution: SIGA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.7); meanwhile ANTX trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 65.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ANTX leads the Growth & Scale pillar: SIGA posts -49.7% YoY revenue growth and -65.3% YoY earnings growth on $52M TTM revenue (23.4% gross margin, -14.2% operating margin), compared with ANTX at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, SIGA generates $52M in USD-normalized revenue versus N/A for ANTX. In operating R&D and SG&A reinvestment, SIGA deploys 37.6% of Rev ($20M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ANTX.

SIGA screens cheaper on headline valuation multiples. SIGA trades at 2.5x Forward P/E, N/M Trailing P/E, 3.37x PEG, and 1.4x EV/Revenue (-22.1% FCF margin), whereas ANTX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SIGA (0.4% ROE) versus ANTX (-51.3% ROE) capital efficiency.

In options market volatility and institutional positioning, SIGA carries 81.4% implied volatility (8th %ile, Compressed (<25th %ile)), a 0.04x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.75β · 65% Vol realized risk). By comparison, ANTX carries 134.2% implied volatility (22nd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (0.75β · 98% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.